CBFB::MYH11 MRD after the second chemotherapy cycle: a guide for allogeneic transplantation in favorable-risk AML - PubMed
2 days ago
- #favorable-risk AML prognosis
- #CBFB::MYH11 AML
- #MRD-guided allo-HCT
- CBFB::MYH11-rearranged AML is favorable-risk but has a 40% relapse rate; minimal residual disease (MRD) monitoring is crucial.
- Post-cycle 2 CBFB::MYH11 transcript levels ≥1% are the strongest prognostic marker for inferior disease-free and overall survival, guiding treatment.
- Allogeneic hematopoietic cell transplantation in first complete remission improves disease-free survival for high-risk patients with MRD ≥1% after cycle 2.